NSAIDs: More Bad News
NSAIDs are an $11-12+ billion market, yet the problems with these drugs continue to make headlines. The most recent study examined data from nearly 450,000 patients, and concluded (our…
Menu
Control or Collaboration – Value Creation & Success Focus
The following commentary is from Mr. Tom Brya, Managing Director at Titenare GXL. Titenare is an international consultancy providing integrated, knowledge-based services and solutions to pharma companies internationally. For further…